Amid the uncertainty, researchers, clinicians, and pharmaceutical companies rose to face one of the greatest medical challenges of our time.
In March 2020 the United States was in the early stages of the coronavirus disease 2019 (COVID-19) pandemic. We shut down the entire country and ground the economy to a halt to slow the spread of the virus. It was a time of incredible uncertainty.
Now, a mere 9 months later, the FDA has approved 2 COVID-19 vaccines for use under emergency authorization. By New Year’s Day 2021, millions of Americans had received the vaccine, including frontline physicians, health care providers, and nursing home patients, our most vulnerable citizens.
Nine months. Take a moment and think about that.
At times, the mainstream media has crafted a narrative about the COVID-19 pandemic that’s almost entirely negative. They have often described the US response to the pandemic as blundering from 1 mistake to the next. This narrative is false.
There is of course, another way—perhaps a more accurate and underappreciated way—to tell the story of the past 9 months. It is a story of heroism, innovation, and precise science, performed under unbelievable pressure.
Let’s not mince words: The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians, and business leaders—who are working tirelessly to rescue the world from COVID-19. It’s the medical breakthrough of our lifetime.
Instead of dwelling on why many in the media are ignoring this, let’s review some facts.
The next step of the process—distribution of the vaccine—has been as challenging as the development phase, if not more so. But the pharmaceutical industry is once again rising to the occasion and factories worldwide are working overtime to produce hundreds of millions of vaccine doses.
Less than a month after the Pfizer vaccine was approved, more than 15.4 million doses of vaccine have been distributed throughout the country, and more than 4.6 million individuals have received their first dose, according to CDC data. Many patients are already receiving their second dose.
Although 15.4 million doses are impressive, some expected 20 million doses. But that is moving the goal line, as 6 months ago many observers didn’t think a vaccine would be available until 2021.
Members of our COVID Coalition told us that the holidays slowed the rollout considerably. But every day, more people will be vaccinated. After health care workers and our most vulnerable citizens, other frontline workers will be next. Teachers will be vaccinated so our children can return to school. And soon, all Americans will be able to receive the vaccine at their doctor’s office or at a CVS or Walgreens.
Remember, we accomplished this in 9 months, with the help, dedication, and expertise of our pharmaceutical industry heroes. Next time you turn on the TV and see negativity, turn it off and imagine instead where we will be in 9 months.
Mike Hennessy Sr is the founder and chairman of MJH Life Sciences™.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.